Loading...
Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination
Abstract
OBJECTIVES: Coronavirus 2019 vaccine responses in rare autoimmune rheumatic diseases (RAIRDs) remain poorly understood; in particular there is little known about whether people develop effective T cell responses. We conducted an observational study to evaluate the short-term humoral and cell-mediated T cell response after the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in RAIRD patients compared with healthy controls (HCs). METHODS: Blood samples were collected after the second dose and anti-spike, anti-nucleocapsid antibody levels and SARS-CoV-2-specific T cell responses were measured and compared with those of HCs. Activation-induced marker and deep phenotyping assays were used to identify differences in T cells between high and no/low antibody groups, followed by multidimensional clustering. RESULTS: A total of 50 patients with RAIRDs were included (31 with AAV, 4 with other systemic vasculitis, 9 with SLE and 6 with myositis). The median anti-spike levels were significantly lower in RAIRD patients compared with HCs (P Copyright © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Citations
Altmetric:
Date
2023
Type
Article
Subject
COVID-19, COVID-19 vaccines, Rheumatic diseases, SARS-CoV-2
Collections
Citation
Gumber, L., Gomez, N., Hopkins, G., Tucis, D., Bartlett, L., Ayling, K., Vedhara, K., Steers, G., Chakravorty, M., Rutter, M., Jackson, H., Tighe, P., Ferraro, A., Power, S., Pradere, M., Onion, D., Lanyon, P.C., Pearce, F.A. and Fairclough, L. (2023) 'Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination', Rheumatology, 62(6), pp. 2294-2303. doi: 10.1093/rheumatology/keac574 https://doi.org/10.1093/rheumatology/keac574.